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Severe drug-induced liver injury associated with prolonged use of 
linezolid 
 
Abstract 
Objective: To describe a patient developing concomitant severe liver failure and lactic 
acidosis after long-term treatment with linezolid. 
Case Summary: A 55-year old Caucasian woman developed concomitant severe liver failure 
and lactic acidosis after a treatment with linezolid for 50 days because of infected hip 
prosthesis. Other causes of liver failure and lactic acidosis were excluded by extensive 
diagnostic work-up. A liver biopsy showed microvesicular steatosis. As linezolid toxicity was 
considered to be the cause of the lactic acidosis and the severe hepatic failure, the antibiotic 
was withdrawn. After four days of supportive therapy and  hemodialysis, the serum lactate 
level returned within normal limits. The prothrombin time and thrombocytes recovered within 
two weeks. Bilirubin levels normalized within 14 weeks. 
Discussion: Since no other cause could be identified, liver injury was considered to be drug 
related. Resolution of the hepatotoxicity occurred after discontinuation of linezolid, 
supportive treatment measures and hemodialysis. Both lactic acidosis after the use of linezolid 
and microvesicular steatosis are related to mitochondrial dysfunction. The Council for 
International Organizations of Medical Sciences/Roussel Ucalf Causality Assessment Method 
scale, revealed that the adverse drug event was probable.  
Conclusion: Prolonged exposure to linezolid may induce severe hepatotoxicity. Clinicians 
should be aware of this possible adverse effect especially in case of long-term treatment. 
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Introduction 
Infection of prosthetic devices is frequently caused by Gram-positive pathogens and 
requires prolonged antibiotic treatment in order to achieve microbial eradication. When 
methicillin-resistant staphylococci are involved, linezolid is a recommendable therapeutic 
option as it shows excellent activity against these pathogens and as it has a 100% oral 
bioavailability.[1] As such, it can be administered orally and on an outpatient basis, whereas 
treatment with glycopeptides requires intravenous access, which often implies prolonged 
hospitalization. 
Serious side effects of linezolid therapy have been described, including bone marrow 
toxicity, peripheral and optic neuropathy, and lactic acidosis.[2,3,4] Lactic acidosis has been 
reported almost exclusively in patients treated for longer than the maximum recommended 
duration of 28 days. In this report we describe a case of severe drug-induced liver injury 
(DILI) related to the use of linezolid. 
 
Case Report 
A 55-year old woman with rheumatoid arthritis was hospitalized for malnutrition and 
chronic infection in a prosthetic hip. Upon admission alkaline phosphatase and gamma-
glutamyltransferase levels were elevated respectively 4 and 6 times the upper limit values. 
The hip prosthesis was removed a few days later and oxacillin was started. Transient elevation 
in transaminases, alkaline phosphatase and gamma-glutamyltransferase (without increase in 
bilirubin) prompted a diagnostic work-up for liver disease.  On abdominal ultrasound, biliary 
ducts were not dilated, liver parenchyma had a homogeneous aspect, and portal and hepatic 
circulation were normal. Hepatitis viral serology was negative. Ceruloplasmine, serum copper 
concentration and alpha 1-antitrypsin were normal. Transaminase levels returned to normal 
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limits within one week, followed by a slower decrease of alkaline-phosphatase and gamma-
glutamytransferase levels, which returned to the patients’ baseline values. 
Initial treatment with oxacillin was changed to vancomycin, followed by teicoplanin, 
which in turn were replaced by linezolid after 10 weeks because of glycopeptide-related renal 
toxicity (vancomycin) and thrombocytopenia (teicoplanin). Meropenem was added for 
coverage of Gram-negative pathogens. With this antibiotic regimen, the patient improved 
clinically and inflammatory parameters decreased gradually, but symptoms of anorexia and 
weight loss persisted, necessitating placement on parenteral nutrition. She was discharged 
from the hospital 4 months after the removal of the prosthesis.  Six days later she was re-
admitted to the emergency department with general weakness and itching, right 
hypochondrial and epigastic pain, nausea and vomiting since four days. Her family had 
noticed yellow discoloration of the sclerae since two days. At that time, she was taking 
linezolid (600 milligrams every 12 hours) and meropenem (one gram every eight hours) for 
respectively 50 days and was receiving home total parenteral nutrition (Structokabiven 12g N 
(Fresenius®), supplemented with vitamins and oligo-elements) for 36 consecutive days. 
Additional medication consisted of vitamin D, calcium, domperidon, esomeprazol, 
enoxaparine and dorzolamide- timolol eye drops. 
Upon admission clinical examination showed an icteric and dehydrated patient in poor 
general condition. Her vital signs were a temperature of 37°C, a pulse rate of 103/min, a 
blood pressure of 11/6 cmHg and a respiratory rate of 36/min. The abdomen was tender, 
especially in the right hypochondric region, but there was no peritoneal irritation. On 
admission blood analysis showed a severe lactic acidosis: pH 7.27 (normal 7.35-7.45), 
bicarbonate 11.2 mmol/l (normal 22-26), lactate 121 mg/dl (normal 9-16) and cholestasis 
(gamma-glutamyltransferase 559 U/l (normal 9-36), alkaline phosphatase 2486 U/l (normal 
30-120), total bilirubin 12.1 mg/dl (normal 0.3-1.2), direct bilirubin 8.83 mg/dl (normal 0-
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0.30). Transaminases were slightly elevated: aspartate aminotransferase (AST) 97 U/l (normal 
0-31), alanine aminotransferase (ALT) 113 U/l (normal 7-31) and thrombocytopenia was 
present: 84.000/µl (normal 177.000-393.000). The prothrombin time was 50% (normal 70-
120). The prothrombin time, expressed as percentage, is The serum ammonia was elevated up 
to 86 µmol/l (normal 11-48). She also had a mild elevation of the serum creatinine on 
admission of 1.07 mg/dl (normal 0.55-0.96). 
The patient was admitted to the intensive care unit because of progressive 
encephalopathy, grade 3 (presence of apathy and somnolence and disorientation). In the 
presence of impaired synthetic function (decreased prothrombin time and spontaneous 
hypoglycaemia) encephalopathy and icterus having occurred within less than six weeks , a 
diagnosis of acute liver failure was made. Initially, she was hemodynamically and respiratory 
stable. There were no signs of cardiac ischemia based on cardiac enzymes, 
electrocardiography and transthoracic echocardiography. There were no focal signs of 
intercurrent infection. Linezolid, meropenem and total parenteral nutrition were discontinued 
and continuous hemodialysis was started because of persistent lactic acidosis within 24h of 
ICU admission. 
Further investigations were performed. Viral serology and antimitochondrial 
antibodies were negative. Antinuclear factor was positive, which was attributed to rheumatoid 
arthritis. Anti-smooth muscle antibodies were mildly elevated. There was no hepatomegaly 
nor dilatation of the biliary ducts on abdominal ultrasound and Magnetic Resonance 
Choledochopancreaticography (MRCP). The liver parenchyma had a heterogenous aspect on 
Magnetic Resonance Imaging (MRI). The duplex doppler examination of the liver and portal 
system was normal. A Computed Tomography (CT) scan of the abdomen showed a diffuse 
oedematous thickening of the small intestine wall and colon wall, and the presence of intra-
abdominal free fluid. During a diagnostic explorative laparoscopy, for which she was 
  
5 
 
electively intubated, there were no arguments for ischemia of small and large intestine. The 
blood supply to all other abdominal organs was preserved. A liver with a rough surface but 
normal size was seen. A subcapsular liver biopsy was performed. Light microscopy revealed 
preserved architecture of the liver parenchyma, with the presence of diffuse and mainly 
microvesicular steatosis. The pas-diastase staining revealed several ceroid macrophages, 
which were mainly localized in the centrolobular area. Some interlobular bile ducts showed a 
flattened, damaged epithelium and the staining for cytokeratin 7 revealed that some portal 
tracts contained no bile duct. In agreement with these findings, the cytokeratin 7 staining also 
showed periportal ductular reaction and cholate stasis. Overall, this subcapsular liver biopsy 
showed diffuse microvesicular steatosis and features compatible with toxic parenchymal liver 
damage with associated bile duct damage (Figures).  
The patient could not be weaned from the ventilator postoperatively due to the 
encephalopathy. Lactic acidosis resolved over a few days. Hemodialysis was discontinued 
after four days and enteral nutrition was started. The prothrombin time increased but 
cholestasis persisted. Repetitive ultrasound revealed no dilated intra- or extrahepatic bile 
ducts. The patient was weaned from the ventilator after 12 days of mechanical ventilation, and 
could be discharged from the intensive care unit (ICU) after 16 days. Bilirubin levels 
normalized within 14 weeks. In this period alkaline phosphatase and gamma-
glutamyltransferase levels returned to the patients’ baseline values (Graphs). 
Meropenem was restarted one month later because of persisting osteomyelitis, and no 
increases in liver function tests were observed. The patient however died 4 months after her 
first ICU admission because of uncontrollable septic shock. 
 
Discussion 
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Our patient presented with lactic acidosis and fulminant liver failure, as shown by the 
development of icterus and encephalopathy within less than 6 weeks; hypoglycaemia and a 
rise in INR were further signs of liver failure. Linezolid was thought to be the probable cause 
of this event. Drug-induced liver injury (DILI) has been associated with the use of nearly 1000 
drugs, and may mimic all forms of acute and chronic hepatobiliary disease.[5,6] Establishing 
a definite diagnosis of DILI is challenging and often impossible. Cornerstones in establishing 
a likely diagnosis of DILI are the exclusion of other etiologies of liver injury, a time course 
congruent with the introduction of the drug and recovery after withdrawal of the drug, and a 
clinical and/or histological signature compatible with postulated mechanisms of drug-
induced toxicity. The Council for International Organizations of Medical Sciences/Roussel 
Ucalf Causality Assessment Method scale [6,7,8], is developed to quantify the strength of the 
association between hepatic injury and medication as its suspected cause, (implicated as 
causing the injury.) The system comprises seven weighted criteria (time to onset following 
initial drug exposure, course of the reaction, presence of risk factors, concomitant drug 
exposure, exclusion of non-drug causes of liver injury, previous information regarding the 
known hepatotoxic potential of the drug and response to re-challenge), that are tabulated and 
taken into consideration in a graded fashion along with the type of liver injury (hepatocellular 
or cholestatic/mixed). We found a score of 6 in our patient, which corresponds to a probable 
association between linezolid and DILI. DILI was complicated by acute liver failure, since 
icterus and encephalopathy developed within a time frame of 6 weeks; additional signs of 
liver failure were hypoglycemia and a decrease in prothrombin time. (the occurrence of 
microvesicular steatosis with acute liver failure was probable (score 6).) Elevation of liver 
enzymes in patients treated with linezolid have been described before, but severe DILI or liver 
failure has not yet been reported. (Linezolid use may occasionally be associated with 
abnormalities in liver enzymes.[4] (The degree of derangement varies, likely based on the 
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patient population and associated comorbidities.) Liver failure related to the use of linezolid 
however has not been reported before) 
(In our patient,)  We intensively sought for alternative causes of liver injury. 
Screening tests for viral hepatitis, hereditary hemochromatosis, α1- antitrypsin deficiency and 
Wilson’s disease were negative, and medical imaging ruled out biliary obstruction, cardiac 
dysfunction or hepatic vascular abnormality.  The liver did not show ischemia on laparoscopy. 
(There was no dilatation of the biliary ducts on abdominal ultrasound and MRCP, and 
vascular abnormalities were ruled out by duplex doppler examination of the liver and portal 
system. Peroperative there were no arguments for ischemia. Echocardiography showed a 
normal left ventricular function. Our patient had a positive antinuclear factor test and a mildly 
positive anti-smooth muscle antibodies. However) Despite the presence of some anti-smooth 
muscle antibodies, light microscopy of the liver biopsy showed no (evidence for) auto 
immune hepatitis or primary biliary cirrhosis. (An immune-mediated idiosyncratic reaction 
characterised by the presence of fever, rash, eosinophilia and auto-antibodies (such as 
antinuclear and smooth muscle antibodies) is described with DILI.[6] ) 
 We reckoned toxicity induced by therapy given alongside linezolid, more precisely 
meropenem and total parenteral nutrition. (The patient was taking linezolid and meropenem 
for respectively 50 days and was receiving home total parenteral nutrition for 36 consecutive 
days.) Parenteral nutrition is a known cause of  liver dysfunction, ranging from mild 
elevations of serum aminotransferases, alkaline phosphatase and bilirubin, to steatosis, 
steatohepatitis (predominantly in adults), and cholestastis (predominantly in infants). When 
steatosis is related to the use of parenteral nutrition, macrovesicular steatosis is the 
predominant finding observed on biopsy specimen.[9] Scarce articles describe both 
microvesicular and macrovesicular steatosis with the use of parenteral nutrition.[10] The 
purely microvesicular steatosis with associated bile duct damage in our patient, coupled with 
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the fulminant course of liver dysfunction, argues against parenteral nutrition as main etiology. 
The possibility remains however that total parenteral nutrition has contributed to the 
development of severe DILI. ( predisposed our patient to develop severe liver injury by 
linezolid.) 
Elevation of liver function tests during meropenem therapy has been described in 2 to 
5 percent of the treated patients.[11] A more thorough search of the literature showed no 
reports on severe hepatic failure or microvesicular steatosis. In our patient meropenem was 
rechallenged in September during a new septic episode due to osteomyelitis without 
recurrence of elevation of the transaminases. (liver function tests.) 
 
Linezolid use may occasionally be associated with abnormalities in liver enzymes.[4] 
The degree of derangement varies, likely based on the patient population and associated 
comorbidities. Liver failure related to the use of linezolid however has not been reported 
before. As linezolid toxicity was considered to be the cause of the lactic acidosis and the 
concomitant hepatic failure, the antibiotic was withdrawn. As the metabolic acidosis could not 
be controlled with a continuous sodiumbicarbonate infusion, hemodialysis was started. 
Thiamine has been used in the treatment of linezolid-induced lactic acidosis, but is no proven 
therapy.[12] Our patient already received thiamine at home which was continued. Lactate 
levels normalized within four days, INR, fibrinogen and thrombocytes recovered within two 
weeks, but cholestasis persisted. This time course is congruent with that of previous case 
reports of patients surviving linezolid-induced lactic acidosis, which showed  resolution of 
hyperlactatemia within 2 days to 2 weeks following linezolid withdrawal.[12] Noteworthy,  
resolution of DILI after to drug withdrawal may be delayed, in particular the cholestatic 
pattern which may take up to 1 year to resolve.[13] 
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In our patient, the predominant pattern of liver histology was that of diffuse 
microvesicular steatosis. Microvesicular steatosis is related to severe impairment of the 
mitochondrial ß-oxidation of fatty acids. It is identified by the presence of small, uniform 
lipid droplets dispersed throughout the hepatocyte, which leave the nucleus in the centre of 
the cell. Microvesicular steatosis is a potentially severe form of hepatotoxicity, which, in 
severe cases, may rapidly evolve to liver failure, coma and death. While some hepatocytes 
exhibit microvesicular fat, other may exhibit macrovacuolar steatosis in the same patient. 
These mixed cases should be classified as microvesicular steatosis, since the latter may entail 
a more severe prognosis.[14,15,16] Various endogenous and exogenous substances impair 
mitochondrial ß-oxidation to cause microvesicular steatosis (Table 2). Our patient was not 
taking any of these medications (associated with the development of microvesicular steatosis), 
and she denied the use of any over-the-counter drugs, herbal products or alcohol.  
Linezolid exerts its antimicrobial effect through inhibition of bacterial protein 
synthesis by binding to the 23S ribosomal RNA of the 50S subunit. The mitochondrial protein 
synthesis machinery is in many ways similar to the prokaryotic machinery and as a result may 
be a collateral target for antibiotics that function by binding to the bacterial ribosome.[17] 
This is well illustrated by the fact that tetracyclines, which have a similar microbial target as 
linezolid, are associated with the occurrence of microvesicular steatosis as well.[14] 
Mitochondrial dysfunction is also the key mechanism responsible for linezolid-induced lactic 
acidosis. Previous studies have shown that linezolid induces a dose- and time- dependent 
inhibition of mitochondrial protein synthesis.[2,18] Interestingly, in the lactic acidosis case 
patient of De Vrieze et al., macro- and microvesicular steatosis was also seen on histological 
examination of liver samples. In contrast to our patient, elevation of the liver function tests or 
clinical symptoms associated with liver failure, with the exception of encephalopathy, were 
not mentioned for this case patient who was admitted with optic neuropathy, myopathy, lactic 
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acidosis and renal failure after prolonged use of linezolid. Finally, it should be mentioned that 
other antimicrobial oxazolidinones, more precisely the early derivatives investigated by 
DuPont in the 1980s,[19] and newer potent molecules (PNU-140693 and PNU-141059) [20] 
are known to induce hepatic toxicity in animal models. The association of lactic acidosis with 
microvesicular steatosis and occasionally liver failure has been well known in patients 
receiving nucleoside-analogue reverse transcriptase inhibitors (NRTIs).[21] However, it 
should be noted that NRTIs inhibit the mitochondrial DNA polymerase-γ while linezolid 
inhibits the mitochondrial protein biosynthesis. 
 
The fact that our patient presented with preexisting signs of cholestasis (elevated 
alkaline phosphatase and gamma-glutamyltransferase levels upon admission in April) is a 
limitation in this report. (When the hip prosthesis was removed and oxacillin was started, a 
transient elevation in transaminases, alkaline phosphatase and gamma-glutamyltransferase 
was observed, on the other hand bilirubin and thrombocyte count remained normal. 
Transaminase levels returned to normal limits within one week.) As our patient already had 
received multiple antibiotic regimens and parenteral nutrition, the presence of an underlying 
pre-existing liver injury is possible. However, from the time course of liver function tests, it 
(As transaminases, bilirubin and lactate were normal with the start of linezolid, and as 
alkaline phosphatase and gamma-glutamyltransferase levels already returned to the patients’ 
baseline values (graphs),) shows that treatment with linezolid coincided with the occurrence 
of a new hepatotoxic event (we can assume that the start of linezolid in combination with 
meronem and parenteral nutrition gave rise to a new hepatotoxic event.)  
 
  
11 
 
In conclusion, we report on a patient developing lactic acidosis and DILI with acute 
(fulminant) liver failure, probably related to prolonged use of linezolid. Clinicians should be 
aware of this rare but life-threatening adverse effect.  
 
(Summary 
We describe a case of severe liver injury and lactic acidosis after prolonged use of 
linezolid. Lactic acidosis has been reported almost exclusively in patients treated for longer 
than the maximum recommended duration of 28 days. This report suggests the risk for major 
toxicity associated with prolonged courses of linezolid. Prescribers should be aware of the 
possibility of linezolid induced liver injury when a patient presents with severe cholestasis or 
liver failure. ) weglaten 
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Legends: 
 
Figure 1 : the parenchyma shows diffuse microvesicular steatosis (arrows). (Original  
magnification x400). 
 
Figure 2: portal tract with a mildly increased mononuclear infiltrate and a bile duct  
with damaged, degenerated epithelium containing a lymphocyte (arrow). (Original  
magnification x400). 
 
Figure 3: the CK7-staining shows a portal tract with a damaged bile duct (long arrow),  
periportal ductular reaction (short arrows) and positive periportal hepatocytes,  
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indicating cholate stasis (arrowhead). Note that the stained hepatocytes appear  
vacuolated due to the microvesicular steatosis. (Original magnification x400). 
